Study demonstrates adherence to disease-modifying therapies

Study demonstrates adherence to disease-modifying therapies in pregnant MS patients can reduce hospitalization events


Share this article
Share this article
ORLANDO, Fla., March 1, 2021 /PRNewswire/ -- AllianceRx Walgreens Prime recently announced results from research analyzing data of females with multiple sclerosis (MS) who became pregnant, and the impact of adherence to their disease-modifying therapies (DMTs) on hospital utilization and cost. Researchers wanted to understand how non-adherence to their DMTs would impact healthcare cost and utilization over a two-year period. The findings suggest for those women continuing their therapy throughout pregnancy, hospitalization costs and use were lower, compared to those who discontinued their therapy. The retrospective study was conducted by Walgreens, in collaboration with AllianceRx Walgreens Prime, a leading specialty and home delivery pharmacy.

Related Keywords

, Francis Staskon , Heather Kirkham , Adrienne Foley , Walgreens , Pharmacy Quality Alliance , National Ms Society , Americas Committee For Treatment , Research In Multiple Sclerosis Forum , Alliancerx Walgreens Prime , Market Scan , Americas Committee , Multiple Sclerosis Forum , Prime Therapeutics , ஹீத்தர் கர்க்ஹம் , வால்க்ரீன்ஸ் , மருந்தகம் தரம் கூட்டணி , தேசிய செல்வி சமூகம் , அமெரிக்காக்கள் குழு க்கு சிகிச்சை , ஆராய்ச்சி இல் பல ஸ்க்லரோசிஸ் மன்றம் , அள்ளிஅன்சர்ஸ் வால்க்ரீன்ஸ் ப்ரைம் , சந்தை ஊடுகதிர் , அமெரிக்காக்கள் குழு , பல ஸ்க்லரோசிஸ் மன்றம் , ப்ரைம் சிகிச்சை ,

© 2025 Vimarsana